Some tablets have a straight line pressed across one face, sometimes two lines crossing in the middle. It is one of the first things people notice when they look closely at a pill, and it raises two questions at once: does the line mean the tablet is meant to be broken, and does it help work out what the tablet is? A scored tablet answers the second question better than the first.
A scored tablet has a score, which FDA defines as a debossed line running across the flat surface of the tablet. The score exists to make splitting possible, but a line on its own is not permission to split. For identification, the score is a recorded physical feature, listed in the product’s labeling alongside its imprint, shape, color and size. Scoring only applies to tablets; how to tell a tablet from a capsule or caplet is in tablet vs capsule.
What a scored tablet is, in FDA’s own terms
In its 2013 guidance on tablet scoring, FDA draws a clean distinction between two things people tend to run together. A score is a debossed line across the planar surface of the tablet, a physical feature built in at manufacture. Tablet splitting is a practice: breaking or cutting a higher-strength tablet into smaller portions. The first is about the tablet; the second is about what somebody does with it.
The same guidance is candid about the history. It says there are no standards or regulatory requirements that specifically address the scoring of tablets, and that the agency’s concern grew out of practice outside the pharmacy: insurers and prescribers increasingly recommending that patients split tablets, either to adjust the amount or to save money. FDA’s own research then found possible safety issues, especially with tablets that were not scored or not evaluated for splitting, including variation in content, weight and dissolution between the pieces, and stability problems once a tablet is broken.
Functional scoring: when a line has been tested
FDA’s response was to define what it takes for a score to be trusted. Under the guidance, a scored tablet is evaluated against a set of criteria before its labeling can describe it as having functional scoring. In plain terms:
- The pieces have to behave like whole tablets. Split portions should meet the same finished-product testing as a whole tablet of the equivalent strength, and splitting should lose very little material; the guidance sets the loss of mass between segments at under 3 percent.
- The testing covers real hands. The assessment is meant to be done on tablets split by hand as well as with a tablet splitter, because that is how splitting happens at home.
- Split pieces have to stay stable. The guidance asks for evidence that split portions hold up for 90 days in an ordinary pharmacy container at room temperature and humidity.
- Some tablets should not be scored at all. Modified-release products whose control of drug release could be compromised by splitting should not have a scoring feature.
- No test, no score. New products that do not meet the criteria should not have a score, or any reference to scoring, including words like “bisected”, in their labeling.
Where a product does meet the criteria, the guidance asks for “functional scoring” to be stated in the prescribing information, in the Dosage Forms and Strengths section and in the How Supplied section.
There is one catch worth knowing. For products that were already on the market when the guidance appeared, running this assessment was an option, not a requirement. A score line on an older product therefore tells you the tablet was made with a score, not necessarily that the pieces have been tested against these criteria.
Why a score line is not an instruction
This is the point FDA makes most directly in its consumer page on tablet splitting, and it is the one that matters at home. If a tablet is approved to be split, that information is printed in the How Supplied section of the professional label and in the patient package insert, and the tablet is scored where it should be split. If the labeling says nothing about splitting, FDA has not evaluated whether the two halves match in weight, content, or how they work in the body.
The same page adds some specifics that surprise people:
- Most sustained, controlled or timed release medicines are not meant for splitting.
- Some tablets are unsuitable for a splitter because of their shape and size, even if they appear to be scored.
- When a prescription moves from one brand or manufacturer to another, whether the new tablet can be split has to be confirmed again, because the same medicine can be made differently.
- Split tablets can be affected by heat and humidity, which is why FDA advises against splitting a whole supply in advance and storing the halves, particularly somewhere damp like a bathroom cabinet.
FDA’s summary is blunt: tablet splitting should be done only under the supervision of a healthcare professional. So the useful reading of a score line is modest. It tells you the tablet was designed with splitting in mind, and nothing about whether a particular tablet should be split, or for whom.
Why generics keep the same score
A detail in the guidance explains something people sometimes notice at the pharmacy counter. FDA says the scoring configuration of a generic product should be the same as that of the reference product it copies. The reasoning is practical: consistent scoring lets a patient who has been told to split a tablet do so in the same way whichever manufacturer’s version they receive, and it stops either version gaining a market advantage by being scored when the other is not.
That is why a generic can look completely different from the brand, with a new color, shape and imprint, yet still carry the same number of score lines. The appearance is the manufacturer’s choice; the score configuration is meant to match. Why the rest of the appearance changes so freely is covered in why your refill looks different.
The score as an identification clue
For identification, a score is more useful than people expect, because it is written down. For tablets and capsules, the labeling on DailyMed, the National Library of Medicine’s library of FDA labeling, typically includes a small table of product characteristics: color, score, shape, size, flavor and imprint code. The score entry reads “no score” or gives the number of pieces the score divides the tablet into, such as “2 pieces”.
That makes the score a checkable feature rather than a vague impression. If a tablet in your hand has a single clear line and the product you suspect is recorded as “no score”, something does not match. If a tablet has a cross-shaped score, that narrows the field further still.
Three practical points when reading a score:
- A score is not an imprint. Federal rules in 21 CFR Part 206 require a code imprint on most solid oral medicines, and it is the imprint, read together with size, shape and color, that identifies the product. The score is supporting evidence. How imprint codes work is explained in what pill imprint codes mean.
- Look at both faces. Some tablets are scored on one side and imprinted on the other, and some carry characters on either side of the line. A photograph of only one face can miss half the evidence.
- Low, side-on light shows it best. A shallow score, like a shallow imprint, can vanish under a flash and stand out clearly in raking light. The technique is set out in how to photograph a pill so the imprint is readable.
Shape and color alone narrow the field without settling it, for the reasons in pill identifier by color and shape. The score is one more feature in the same family: helpful for ruling candidates out, never enough on its own to rule one in.
Half a tablet in the organizer
The most common reason a score comes up at home is a half tablet: one found loose in a pill organizer, or at the bottom of a bag, broken neatly along its line. A broken tablet is harder to identify because part of the imprint may be on the missing piece. Here the score earns its place: a clean break along a line, plus whatever characters survive on the remaining half, plus the DailyMed score entry, often narrows the candidates to a handful. Keep the half with anything else from the same container, note where it was found, and let a pharmacist, who can compare it with what was dispensed in the household, make the final call.
Sources
- Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation (Guidance for Industry, March 2013), U.S. Food and Drug Administration
- Tablet Splitting, U.S. Food and Drug Administration
- DailyMed, U.S. National Library of Medicine
- Part 206, Imprinting of Solid Oral Dosage Form Drug Products for Human Use, eCFR